dementia Archives

The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein

Listen: Helen Branswell on monkeypox, plus: an FDA controversy and fake Alzheimer’s data

The Readout LOUD Damian Garde and Adam Feuerstein

Listen: VC malaise, FDA confusion, & yet another Alzheimer’s debate

Biotech Adam Feuerstein

The biotech scorecard for the third quarter: 18 stock-moving events to watch

The Readout LOUD Damian Garde, Meg Tirrell and Adam Feuerstein

Listen: Paul Offit on Covid vaccines for kids, plus: how the Fed affects biotech, & another Alzheimer’s setback

Pharma Adam Feuerstein

A Roche treatment fails to slow cognitive decline in patients with inherited form of Alzheimer’s disease

The Readout LOUD Damian Garde, Meg Tirrell and Adam Feuerstein

Listen: Succession at Biogen, surprises at Vertex, & a potential superspreader dinner

First Opinion Anand Kumar

Exploitation in the name of biomedical innovation cannot be tolerated

D.C. Diagnosis Nicholas Florko

The FDA’s Rob Califf on importing drugs from Canada, on Aduhelm, and on opioids

Insurance Bob Herman

UnitedHealthcare restricts coverage of Aduhelm, following Medicare

Biotech Adam Feuerstein and Damian Garde

Biogen board slashes CEO’s bonus as Aduhelm sales and overall business struggle

Politics Nicholas Florko

Medicare’s Brooks-LaSure expects restrictions on accelerated approval drugs, like those for Aduhelm, to be ‘very rare’

D.C. Diagnosis Nicholas Florko

The next battle in the never-ending war over Aduhelm

Politics Nicholas Florko

Will Biogen sue Medicare over its restrictions on the Alzheimer’s drug, Aduhelm? And other big legal questions about the decision

First Opinion John N. Mafi and Catherine Sarkisian

Medicare got it right: Unproven Alzheimer’s drug would have threatened the financial stability of 60 million Americans

Politics Rachel Cohrs

Medicare finalizes its restrictions on new Alzheimer’s drug, despite pressure from drugmakers

D.C. Diagnosis Nicholas Florko

Faced with high drug prices, seniors are abandoning cancer drugs at the pharmacy

Adam's Take Adam Feuerstein

Troubles mount for Cassava Sciences, as patient enrollment lags for Alzheimer’s drug studies

Politics Nicholas Florko

Califf admits controversy over FDA’s Alzheimer’s drug decision impacted experts’ trust in the agency

Health Tech Katie Palmer

With pharma still struggling in Alzheimer’s, health tech companies want a swing

D.C. Diagnosis Nicholas Florko

Before Aduhelm, Billy Dunn was a superstar at the FDA

Politics Nicholas Florko

Lawmakers face off about the future of the FDA’s accelerated approval pathway

Politics Rachel Cohrs

Medicare premiums could decrease ‘soon,’ after decision on Alzheimer’s drug Aduhelm

Biotech Matthew Herper

Biogen publishes data on its Alzheimer’s drug in a little-known journal

Biotech Adam Feuerstein and Damian Garde

With Aduhelm in limbo, Biogen starts laying off employees

Biotech Damian Garde

dementia

Most Read

It’s time to move past Aduhelm and focus on a broader Alzheimer’s drug pipeline

Costly Alzheimer’s treatment is spreading around the world, with virtually no science to back it up

Key Senate committee proposes a council to ensure FDA better coordinates on accelerated approvals

Transfusion of brain fluid from young mice is a memory-elevating elixir for old animals

CMS made the wrong decision on Aduhelm. But there might be a silver lining

Biogen’s reckoning: How the Aduhelm debacle pushed a troubled company and its fractured leadership to the brink

Inside ‘Project Onyx’: How Biogen used an FDA back channel to win approval of its polarizing Alzheimer’s drug

Using human brain tissue in lab dishes, researchers show herpes link to Alzheimer’s

All Coverage

Listen: Helen Branswell on monkeypox, plus: an FDA controversy and fake Alzheimer’s data

Listen: VC malaise, FDA confusion, & yet another Alzheimer’s debate

The biotech scorecard for the third quarter: 18 stock-moving events to watch

Listen: Paul Offit on Covid vaccines for kids, plus: how the Fed affects biotech, & another Alzheimer’s setback

A Roche treatment fails to slow cognitive decline in patients with inherited form of Alzheimer’s disease

Listen: Succession at Biogen, surprises at Vertex, & a potential superspreader dinner

Exploitation in the name of biomedical innovation cannot be tolerated

The FDA’s Rob Califf on importing drugs from Canada, on Aduhelm, and on opioids

UnitedHealthcare restricts coverage of Aduhelm, following Medicare

Biogen board slashes CEO’s bonus as Aduhelm sales and overall business struggle

Medicare’s Brooks-LaSure expects restrictions on accelerated approval drugs, like those for Aduhelm, to be ‘very rare’

The next battle in the never-ending war over Aduhelm

Will Biogen sue Medicare over its restrictions on the Alzheimer’s drug, Aduhelm? And other big legal questions about the decision

Medicare got it right: Unproven Alzheimer’s drug would have threatened the financial stability of 60 million Americans

Medicare finalizes its restrictions on new Alzheimer’s drug, despite pressure from drugmakers

Faced with high drug prices, seniors are abandoning cancer drugs at the pharmacy

Troubles mount for Cassava Sciences, as patient enrollment lags for Alzheimer’s drug studies

Califf admits controversy over FDA’s Alzheimer’s drug decision impacted experts’ trust in the agency

With pharma still struggling in Alzheimer’s, health tech companies want a swing

Before Aduhelm, Billy Dunn was a superstar at the FDA

Lawmakers face off about the future of the FDA’s accelerated approval pathway

Medicare premiums could decrease ‘soon,’ after decision on Alzheimer’s drug Aduhelm

Biogen publishes data on its Alzheimer’s drug in a little-known journal

With Aduhelm in limbo, Biogen starts laying off employees

Awaiting ‘definitive’ Alzheimer’s drug data, Roche and Genentech launch ambitious new study

You've been selected! STAT+ for less than $2/day

Subscribe to STAT+ for less than $2 per day